nephrologylinx Medical News

Nephrology

Become a Member Today!

Email
Password
Remember me
Forgot your Password?
Invite Code?

Home
General Nephrology

Messages

Conferences

Jobs

Newsletters

My Library

Topics in
Nephrology

Acid-Base

Basic Science/Genetics

Chronic Dz/Renal Failure

Cystic Dz

Dialysis

Economics of Medicine

Endocrinology

Fluids and Electrolytes

Glomerular/Tubular Dz

Hematology/Oncology

Hypertension

Nephropathies

Pediatric Nephrology

Pharmacology/kinetics

Popular Press

Radiology/Diagnostics

Stone Disease

Transplantation

Ureteral Disease

Vascular

Help

Resource Center

RSS News Feeds

Send Newsletter
to a Friend

Sponsor

Article Summary

Click the title below to leave the MDLinx Network and go to the Journal's Website

Efficacy and cardiovascular safety of daclizumab, mycophenolate mofetil, tacrolimus, and early steroid withdrawal in renal transplant recipients: a multicenter, prospective, pilot trial
Clinical Transplantation, 07/26/05

Email This Article

Save in My Library

Free Abstract

This single-arm, open-label, pilot study was designed to assess the efficacy and cardiovascular safety profile of daclizumab, a humanized monoclonal interleukin (IL)-2R antibody, in combination with mycophenolate mofetil (MMF), tacrolimus, and early corticosteroid withdrawal in renal transplant recipients

Sponsor

Read a Different Specialty

Allergy/Immunology
Anesthesiology
Cardiology
Dermatology
Drugs
Emergency Medicine
Endocrinology
ENT

Family Medicine
Gastroenterology
Hematology-Oncology
Infectious Disease
Internal Medicine
Nephrology
Neurology
OB/Gyn
Ophthalmology

Orthopedics
Pediatrics
Psychiatry
Pulmonology
Radiology
Rheumatology
Surgery
Urology

Profession Index

Dentist
Hospital Administrator
Nurse

Medical Students
Nurse Practitioner
Pharma/Drug Marketer

Pharmacist
Physician
Physician Assistants

Article Search

Keyword:

Search:

Published within:

Sort By:
Date Relevance

Sponsor